Erythropoietin as antihypoxic cytokine

Abstract

This study analyzed the potential for the widespread use of erythropoietin, the main antihypoxic cytokine produced by renal parenchyma cells, and possible complications associated with its use. Erythropoietin is a glycoprotein heterodimer whose main function is the regulation of the formation and differentiation of erythroid germ cells and formation of the primary physiological response to hypoxia. The main effects of this cytokine are summarized, and the main points of application of the hormone, mechanisms of content regulation, and its use in medicine as a natural pharmacological agent in pharmacological preconditioning are highlighted. Attention is also drawn to the increasing role of hypoxia — one of the most dangerous typical pathological processes in the formation of life-threatening conditions, which has found its use in medicine, particularly as a physiological agent in combating vascular diseases, which are gaining enormous importance in our time.

Keywords

hypoxia / erythropoietin / pharmacological preconditioning / erythrocyte / hypoxia-inducible factor 1

References

[1] Boyko AN, Sidorenko TV, Kabanov AA. Khronicheskaya ishemiya mozga (distsirkulyatornaya entsefalopatiya). Consilium medicum. 2004;6(8):598–601. EDN: WJJMFH

[2] Бойко А.Н., Сидоренко Т.В., Кабанов А.А. Хроническая ишемия мозга (дисциркуляторная энцефалопатия) // Consilium medicum. 2004. Т. 6, № 8. С. 598–601. EDN: WJJMFH

[3] Gusev EI, Skvortsova VI. Cerebral ischemia. Moscow: Meditsina Publ.; 2001. 328 p. (In Russ.)

[4] Гусев Е.И., Скворцова В.И. Ишемия головного мозга. Москва: Медицина, 2001. 328 с.

[5] Pal’chik AB, Shabalov NP. Hypoxic-ischemic encephalopathy of the newborn: A guide for physicians. Saint Petersburg: Piter Publ.; 2000. 218 p. (In Russ.)

[6] Пальчик А.Б., Шабалов Н.П. Гипоксически-ишемическая энцефалопатия новорожденных: Руководство для врачей. Санкт-Петербург: Питер, 2000. 218 с.

[7] Kulagin VK, Boldina IG. Basic principles of hypoxia control in shock. Pathological physiology and experimental therapy. 1981;25(4):10–15. (In Russ.)

[8] Кулагин В.К., Болдина И.Г. Основные принципы борьбы с гипоксией при шоке // Патологическая физиология и экспериментальная терапия. 1981. Т. 25, № 4. С. 10–15.

[9] Mazurkevich GS, Dzhurko BI, El’skii VN. Shock: Theory, clinic, organization of shock treatment. Mazurkevicha GS, Bagnenko SF, editors. Saint Petersburg: Politekhnika Publ.; 2004. 539 p. (In Russ.)

[10] Мазуркевич Г.С., Джурко Б.И., Ельский В.Н. Шок: Теория, клиника, организация противошоковой помощи / под ред. Г.С. Мазуркевича, С.Ф. Багненко. Санкт-Петербург: Политехника, 2004. 539 с.

[11] Litvitskii PF. Pathophysiology. Moscow: GEOTAR; 2003. (In Russ.)

[12] Литвицкий П.Ф. Патофизиология. Москва: ГЕОТАР, 2003.

[13] Chesnokova NP, Ponukalina EV, Bizenkova MN. Modern conceptions of hypoxia pathogenesis. Hypoxia classification and the starters of its development. Modern high-tech technologies. 2006;(5):23–25. EDN: JRGOLR

[14] Чеснокова Н.П., Понукалина Е.В., Бизенкова М.Н. Современные представления о патогенезе гипоксий. Классификация гипоксий и пусковые механизмы их развития // Современные наукоемкие технологии. 2006. № 5. С. 23–25. EDN: JRGOLR

[15] Zenko MYu, Rybnikova EA. Pharmacological preconditioning. Integrative physiology. 2020;1(1):32–39. doi: 10.33910/2687-1270-2020-1-1-32-39

[16] Зенько М.Ю., Рыбникова Е.А. Фармакологическое прекондиционирование // Интегративная физиология. 2020. Т. 1, № 1, С. 32–39. doi: 10.33910/2687-1270-2020-1-1-32-39

[17] humbio.ru/humbio/physiology [Internet]. Human biology knowledge base: physiology [cited 2023 Oct 8]. Available at: http://humbio.ru/humbio/physiology (In Russ.)

[18] humbio.ru/humbio/physiology [Электронный ресурс]. База знаний по биологии человека: физиология [дата обращения: 08.10.2023]. Режим доступа: http://humbio.ru/humbio/physiology

[19] Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol. 2010;299(1):F1–13. doi: 10.1152/ajprenal.00174.2010

[20] Haase V.H. Hypoxic regulation of erythropoiesis and iron metabolism // Am J Physiol Renal Physiol. 2010. Vol. 299, N. 1. P. F1–13. doi: 10.1152/ajprenal.00174.2010

[21] Zhu H, Jackson T, Bunn HF. Detecting and responding to hypoxia. Nephrol Dial Transplant. 2002;17(1):3–7. doi: 10.1093/ndt/17.suppl_1.3

[22] Zhu H., Jackson T., Bunn H.F. Detecting and responding to hypoxia // Nephrol Dial Transplant. 2002. Vol. 17, N. 1. P. 3–7. doi: 10.1093/ndt/17.suppl_1.3

[23] Maxwell P. Hif-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol. 2003;14(11):2717–2722. doi: 10.1097/01.asn.0000092792.97122.e0

[24] Maxwell P. Hif-1: an oxygen response system with special relevance to the kidney // J Am Soc Nephrol. 2003. Vol. 14, N. 11. P. 2717–2722. doi: 10.1097/01.asn.0000092792.97122.e0

[25] Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol. 2001;28(S8):7–14. doi: 10.1016/s0093-7754(01)90206-4

[26] Ludwig H., Strasser K. Symptomatology of anemia // Semin Oncol. 2001. Vol. 28, N. S8. P. 7–14. doi: 10.1016/s0093-7754(01)90206-4

[27] Skobin VB. Inhibitory effect of tumor necrosis factors on erythropoietin synthesis. VII Russian National Congress: «Human and medicine». Moscow; 2000. 430 p. (In Russ.)

[28] Скобин В.Б. Ингибирующее действие факторов некроза опухолей на синтез эритропоэтина // VII Российский национальный конгресс: «Человек и лекарство». Москва: 2000. 430 с.

[29] Lappin TR, Maxwell AP, Johnston PJ. Epo’s alter ego: erythropoietin has multiple actions. Stem cells. 2002;20(6):482–492. doi: 10.1634/stemcells.20-6-485

[30] Lappin T.R., Maxwell A.P., Johnston P.J. Epo’s alter ego: erythropoietin has multiple actions // Stem cells. 2002. Vol. 20, N. 6. P. 482–492. doi: 10.1634/stemcells.20-6-485

[31] Lin H, Ling Y, Pan J, Gong H. Therapeutic effects of erythropoietin expressed in mesenchymal stem cells for dilated cardiomyopathy in rat. Biochem Biophys Res Commun. 2019;517(4):575–580. doi: 10.1016/j.bbrc.2019.07.053

[32] Lin H., Ling Y., Pan J., Gong H. Therapeutic effects of erythropoietin expressed in mesenchymal stem cells for dilated cardiomyopathy in rat // Biochem Biophys Res Commun. 2019. Vol. 517, N. 4. P. 575–580. doi: 10.1016/j.bbrc.2019.07.053

[33] Wu S-H, Lu I-C, Lee S-S, et al. Erythropoietin attenuates motor neuron programmed cell death in a burn animal model. PLoS One. 2018;13(1):e0190039. doi: 10.1371/journal.pone.0190039

[34] Wu S.-H., Lu I.-C., Lee S.-S., et al. Erythropoietin attenuates motor neuron programmed cell death in a burn animal model // PLoS One. 2018. Vol. 13, N. 1. ID e0190039. doi: 10.1371/journal.pone.0190039

[35] Borodulin VB, Bychkov EN, Protopopov AA, et al. Erythropoietin is a marker of chronic kidney disease at the pre-clinical stage. Fundamental Research. 2013;(11-1):22–26. EDN: RQRURR

[36] Бородулин В.Б., Бычков Е.Н., Протопопов А.А., и др. Эритропоэтин – маркер хронической болезни почек на доклинической стадии // Фундаментальные исследования. 2013. № 11–1. С. 22–26. EDN: RQRURR

[37] Osikov MV, Volodchenko AM, Giniatullin RU. Neuroprotective effect of erythropoietin at experimental spinal cord ischemia. Human. Sport. Medicine. 2017;17(2):40–51. EDN: YRPRND doi: 10.14529/hsm170204

[38] Осиков М.В., Володченко А.М., Гиниатуллин Р.У. Нейропротекторный эффект эритропоэтина при экспериментальной ишемии спинного мозга // Человек. Спорт. Медицина. 2017. Т. 17, № 2. С. 40–51. EDN: YRPRND doi: 10.14529/hsm170204

[39] Osikov MV, Krivohizhina LV, Akhmatov KV, Akhmatov VJu. Hematological effects of erythropoietin in dialysed patients with chronic renal failure. Bulletin of the South Ural State University. Series: education, health care, physical culture. 2009;(20):79–82. EDN: KUDFSD

[40] Осиков М.В., Ахматов К.В., Кривожихина В.Ю., Ахматов В.Ю. Анализ гематологических эффектов эритропоэтина у больных хронической почечной недостаточностью, находящихся на диализе // Вестник Южно-Уральского государственного университета. Cерия: образование, здравоохранение, физическая культура. 2009. № 20. С. 79–82. EDN: KUDFSD

[41] Osikov MV, Akhmatov KV, Fedosov AA. On the mechanism of erythropoietin effect on affective status in patients with chronic renal failure on hemodialysis. Fundamental Research. 2012;(7-1):140–145. EDN: PBAGBB

[42] Осиков М.В., Ахматов К.В., Федосов А.А. К вопросу о механизме влияния эритропоэтина на аффективный статус у больных хронической почечной недостаточностью, находящихся на гемодиализе // Фундаментальные исследования. 2012. № 7–1. С. 140–145. EDN: PBAGBB

[43] Maeda Y, Sakaguchi M, Naiki Y, et al. Possible involvement of soluble erythropoietin receptor in resistance to erythropoietin in patients with renal anemia. Am J Nephrol. 2001;21(5):426. doi: 10.1159/000046289

[44] Maeda Y., Sakaguchi M., Naiki Y., et al. Possible involvement of soluble erythropoietin receptor in resistance to erythropoietin in patients with renal anemia // Am J Nephrol. 2001. Vol. 21, N. 5. P. 426. doi: 10.1159/000046289

[45] Shmonin AA, Panov IYu, Simonenkova AV. Endogenous neuroprotection in cerebral ischemia: erythropoietin, pre- and postconditioning. Annals of clinical and experimental neurology. 2010;4(3):29–35. EDN: LNETGG (In Russ.)

[46] Шмонин А.А., Панов И.Ю., Симоненкова А.В. Эндогенная нейропротекция при ишемии мозга: эритропоэтин, пре- и посткондиционирование // Анналы клинической и экспериментальной неврологии. 2010. Т. 4, № 3. С. 29–35. EDN: LNETGG

[47] Santoso T, Irawan C, Alwi I, et al. Safety and feasibility of combined granulocyte colony stimulating factor and erythropoetin based-stem cell therapy using intracoronary infusion of peripheral blood stem cells in patients with recent anterior myocardial infarction: one-year follow-up of a phase 1 study. Acta Medica Indonesiana. 2011;43(2):112–121.

[48] Santoso T., Irawan C., Alwi I., et al. Safety and feasibility of combined granulocyte colony stimulating factor and erythropoetin based-stem cell therapy using intracoronary infusion of peripheral blood stem cells in patients with recent anterior myocardial infarction: one-year follow-up of a phase 1 study // Acta Medica Indonesiana. 2011. Vol. 43, N. 2. P. 112–121.

[49] Bennis Y, Sarlon-Bartoli G, Guillet B, et al. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J Thromb Haemost. 2012;10(9):1914–1928. doi: 10.1111/j.1538-7836.2012.04835.x

[50] Bennis Y., Sarlon-Bartoli G., Guillet B., et al. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential // J Thromb Haemost. 2012. Vol. 10, N. 9. P. 1914–1928. doi: 10.1111/j.1538-7836.2012.04835.x

RIGHTS & PERMISSIONS

Eco-Vector